Pfizer-partner BioNTech forecasts decline in vaccine sales for full year

Moderna was more bullish last week, forecasting higher vaccine sales for the second half of the year than in the first, as it expects demand for booster shots in the autumn

The German biotech firm is forecasting a full-year decline in vaccine sales.

BioNTech's first-quarter sales and earnings more than tripled thanks to demand for the Covid-19 vaccine it developed with Pfizer, but the German biotech firm is still forecasting a full-year decline in vaccine sales.

Quarterly revenues more than tripled from a year earlier to almost €6.4bn, as did net income, to €3.7bn.